Due to a technical issue, only the tables of contents of the journals and the abstracts of the articles can currently be accessed.We are working on the solution and apologize for any inconvenience.
Diabetologie und Stoffwechsel 2020; 15(06): 450-453
Untersuchung von Polymorphismen in Kandidatengenen für periphere und kardiale autonome Neuropathie in einer bevölkerungsbezogenen Kohorte – Hans-Christian-Hagedorn-Projektförderung 2020 – eine Kurzübersicht des Geförderten Dan Ziegler
Dan Ziegler
Prof. Dr. med. Dr. h. c., FRCPE, Stellv. Direktor und Leiter Arbeitsgruppe Neuropathie am Institut für Klinische Diabetologie, Deutsches Diabetes-Zentrum (DDZ), Leibniz-Zentrum für Diabetes-Forschung an der Heinrich-Heine-Universität Düsseldorf
› Author Affiliations
Literatur
1
Pop-Busui R,
Boulton AJM,
Feldman EL.
et al. Diabetic neuropathy. A statement by the American Diabetes Association. Diabetes Care 2017; 40: 136-154
2
Ziegler D.
Diabetic peripheral and autonomic neuropathy. In:
Holt RIG,
Cockram CS,
Flyvbjerg A.
et al. Eds. Textbook of Diabetes. 5th edition. Oxford (UK): Wiley-Blackwell; 2017: 580-608
3
Ziegler D,
Landgraf R,
Lobmann R.
et al. Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (PROTECT Study). Diabetes Res Clin Pract 2018; 139: 147-154
4
Meisinger C,
Bongaerts BWC,
Heier M.
et al. Neuropathic pain is not adequately treated in the older general population: Results from the KORA F4 survey. Pharmacoepidemiol Drug Saf 2018; 27: 806-814
5
Ziegler D,
Landgraf R,
Lobmann R.
et al
Polyneuropathy is inadequately treated despite increasing symptom intensity in individuals with and without diabetes (PROTECT follow-up study). J Diabetes Investig 2020, Apr 8 [Epub ahead of print]
6
Ziegler D,
Keller J,
Maier C.
et al. DDG-Praxisempfehlung. Diabetische Neuropathie. Diabetologie 2019; 14 (Suppl. 02) S243-S257
7
Ziegler D,
Voss A,
Rathmann W.
for the KORA Study Group.
et al. Increased prevalence of cardiac autonomic dysfunction at different degrees of glucose intolerance in the general population: the KORA S4 survey. Diabetologia 2015; 58: 1118-1128
8
Bönhof GJ,
Herder C,
Strom A.
et al. Emerging biomarkers, tools, and treatments for diabetic polyneuropathy. Endocr Rev 2019; 40: 153-192
9
Spallone V.
Might genetics play a role in understanding and treating diabetic polyneuropathy?. Diabetes Metab Res Rev 2017; 33: e2882
10
Brownlee M.
Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820
11
Hammes HP,
Du X,
Edelstein D.
et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9: 294-299
12
Tanhäuserová V,
Kuricová K,
Pácal L.
et al. Genetic variability in enzymes of metabolic pathways conferring protection against non-enzymatic glycation versus diabetes-related morbidity and mortality. Clin Chem Lab Med 2014; 52: 77-83
13
Ziegler D,
Schleicher E,
Strom A.
for the GDS Group.
et al. Association of transketolase polymorphisms with measures of polyneuropathy in patients with recently diagnosed diabetes. Diabetes Metab Res Rev 2017; 33: e2811
14
Herder C,
Kannenberg JM,
Carstensen-Kirberg M.
et al. A systemic inflammatory signature reflecting crosstalk between innate and adaptive immunity is associated with incident polyneuropathy: KORA F4/FF4 Study. Diabetes 2018; 67: 2434-2442
